Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL309214 | 1.00 | TPH1 (0.71) | TPH1TPH2 | |
| SCHEMBL308048 | 1.00 | TPH1 (0.71) | TPH1TPH2 | |
| SCHEMBL20262049 | 0.84 | TPH1 (0.54) | TPH1TPH2 | |
| SCHEMBL1878104 | 0.82 | TPH1 (0.61) | TPH1TPH2 | |
| SCHEMBL1768132 | 0.82 | TPH1 (0.61) | TPH1TPH2 | |
| SCHEMBL869394 | 0.82 | TPH1 (1.00) | TPH1TPH2 | |
| SCHEMBL869395 | 0.82 | TPH1 (1.00) | TPH1TPH2 | |
| SCHEMBL307738 | 0.80 | TPH1 (1.00) | TPH1 | |
| SCHEMBL307739 | 0.80 | TPH1 (1.00) | TPH1 | |
| SCHEMBL1129387 | 0.80 | TPH1 (0.58) | TPH1TPH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054308-A1 | Methods and Compositions for Treating Pulmonary Hypertension and Related Diseases and Disorders | TERSERA THERAPEUTICS LLC | 2009-02-26 | — | — | US | claimed |
| CN-101351451-A | Polycyclic amino acid derivatives and methods of use thereof | LEXICON GENETICS INC (US) | 2009-01-21 | — | — | CN | claimed |
| US-20070191370-A1 | Multicyclic amino acid derivatives and methods of their use | TERSERA THERAPEUTICS LLC | 2007-08-16 | — | — | US | claimed |
| EP-2386547-B1 | Multicyclic amino acid derivatives and methods of their use | LEXICON PHARMACEUTICALS INC (US) | 2018-06-20 | — | — | EP | disclosed |
| US-9717727-B2 | Methods of treating and preventing leukemia and other cancers of the blood and bone | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2017-08-01 | — | — | US | disclosed |
| US-9150521-B2 | Methods of preventing and treating diabetes by inhibiting serotonin synthesis | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2015-10-06 | — | — | US | disclosed |
| US-20150111908-A1 | METHODS OF DIAGNOSING, PREVENTING, AND TREATING BONE MASS DISEASES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-04-23 | — | — | US | disclosed |
| US-20140378489-A1 | METHODS OF PREVENTING AND TREATING DIABETES BY INHIBITING SEROTONIN SYNTHESIS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2014-12-25 | — | — | US | disclosed |
| US-20140303197-A1 | METHODS OF TREATING AND PREVENTING LEUKEMIA AND OTHER CANCERS OF THE BLOOD AND BONE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2014-10-09 | — | — | US | disclosed |
| US-8759364-B2 | Methods of treating bone mass diseases | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2014-06-24 | — | — | US | disclosed |
| US-8629156-B2 | Tryptophan hydroxylase inhibitors | LEXICON PHARMACEUTICALS, INC. (US) | 2014-01-14 | — | — | US | disclosed |
| US-20090005381-A1 | METHODS OF TREATING SEROTONIN-MEDIATED DISEASES AND DISORDERS | LEXICON PHARMACEUTICALS, INC. | 2009-01-01 | — | — | US | disclosed |
| WO-2009002964-A1 | METHODS OF TREATING SEROTONIN-MEDIATED DISEASES AND DISORDERS | LEXICON PHARMACEUTICALS, INC. (US) | 2008-12-31 | — | — | WO | disclosed |
| WO-2009002964-A1 | METHODS OF TREATING SEROTONIN-MEDIATED DISEASES AND DISORDERS | LEXICON PHARMACEUTICALS, INC. (US) | 2008-12-31 | — | — | WO | disclosed |
| WO-2009002970-A1 | COMPOSITIONS COMPRISING TRYPTOPHAN HYDROXYLASE INHIBITORS | LEXICON PHARMACEUTICALS, INC. (US) | 2008-12-31 | — | — | WO | disclosed |
| WO-2009002970-A1 | COMPOSITIONS COMPRISING TRYPTOPHAN HYDROXYLASE INHIBITORS | LEXICON PHARMACEUTICALS, INC. (US) | 2008-12-31 | — | — | WO | disclosed |
| US-20070191370-A1 | Multicyclic amino acid derivatives and methods of their use | TERSERA THERAPEUTICS LLC | 2007-08-16 | — | — | US | disclosed |
| US-20070191370-A1 | Multicyclic amino acid derivatives and methods of their use | TERSERA THERAPEUTICS LLC | 2007-08-16 | — | — | US | disclosed |
| US-20070191370-A1 | Multicyclic amino acid derivatives and methods of their use | TERSERA THERAPEUTICS LLC | 2007-08-16 | — | — | US | disclosed |
| WO-2007089335-A2 | MULTICYCLIC AMINO ACID DERIVATIVES AND METHODS OF THEIR USE | LEXICON PHARMACEUTICAL INC. (US) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150111908-A1 | METHODS OF DIAGNOSING, PREVENTING, AND TREATING BONE MASS DISEASES | TPH1, HTR1A, TPH2 | TPH1 1/4885TPH2 3/4885 |
| US-20090054308-A1 | Methods and Compositions for Treating Pulmonary Hypertension and Related Diseases and Disorders | TPH1, PAH, TPH2 | TPH1 1/4885TPH2 3/4885 |
| US-20140378489-A1 | METHODS OF PREVENTING AND TREATING DIABETES BY INHIBITING SEROTONIN SYNTHESIS | TPH1, TPH2, HTR1A | TPH1 1/4885TPH2 2/4885 |
| US-20070191370-A1 | Multicyclic amino acid derivatives and methods of their use | AADAT, HNMT, TPH1 | TPH1 3/4885TPH2 4/4885 |
| US-20140303197-A1 | METHODS OF TREATING AND PREVENTING LEUKEMIA AND OTHER CANCERS OF THE BLOOD AND BONE | TPH1, TPH2, HNMT | TPH1 1/4885TPH2 2/4885 |
| US-20090005381-A1 | METHODS OF TREATING SEROTONIN-MEDIATED DISEASES AND DISORDERS | TPH1, TPH2, HNMT | TPH1 1/4885TPH2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.